Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our technology has been used to unlock more undruggable targets than any other AI drug discovery platform. Our discovery engine has been validated by over 600 unique disease targets, across 775 collaborations, spanning more than 250 partners around the world. To date, Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Artificial Intelligence for Drug Discovery We use our AI engine to transform drug discovery. Our discoveries help create better medicines faster. Discovering & Developing New Drugs Our AI-enabled discovery portfolio includes wholly owned and co-developed pipeline assets, and is backed by prominent investors. LEARN MORE ABOUT US OUR PIPELINE Leading Technology Development & Application Atomwise developed a machine learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small molecule medicines. OUR APPROACH OUR PUBLICATIONS Focusing Expertise on the Most Challenging Problems The secret to reinventing drug discovery with AI is people. We are dedicated to developing the best AI platform and using it to transform small molecule drug discovery. MEET OUR TEAM JOIN OUR COMPANY Learn more about our portfolio, pipeline, and career opportunities. CONTACT US Overview Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers Website http://www.atomwise.com Industry Biotechnology Research Company size 51-200 employees Headquarters San Francisco, California Founded 2012 Specialties Machine Learning, Artificial Intelligence, Drug Discovery, and Computer Aided Drug Design
About Atomwise
Atomwise is a biotech company that specializes in using artificial intelligence (AI) to revolutionize drug discovery. Their mission is to create better medicines faster by harnessing the power of deep learning and structure-based drug discovery. Their AI-enabled discovery portfolio includes wholly owned and co-developed pipeline assets, and is backed by prominent investors.
Their AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. Their discovery engine has been validated by over 600 unique disease targets, across 775 collaborations, spanning more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance their mission to make better medicines, faster.
Their machine learning-based discovery engine combines the power of convolutional neural networks with massive chemical libraries to discover new small molecule medicines. Their AI engine transforms drug discovery and helps create better medicines faster. Atomwise is tackling the most challenging problems in drug discovery with a focus on developing the best AI platform and using it to transform small molecule drug discovery.
Atomwise is a preclinical pharma company with a pipeline of small-molecule drug candidates advancing into preclinical studies. They have invented the use of deep learning for structure-based drug discovery and are at a critical time in history where the need for new kinds of medicines is greater than any time in human memory. They leverage advancing technology and scientific breakthroughs to accelerate discovery and empower us to invent and create, and ultimately save one billion lives.
Atomwise's target market is the biotechnology research industry. They cater to pharmaceutical, agrochemical, and emerging biotechnology companies. Their products and services include using AI to discover and develop new drugs. Their roles and main use cases are in drug discovery and development.
Atomwise was founded in 2012 and is headquartered in San Francisco, California. They have 51-200 employees and specialize in machine learning, artificial intelligence, drug discovery, and computer-aided drug design. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline.
In conclusion, Atomwise is a biotech company that specializes in using AI for drug discovery. Their AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform, and they have a pipeline of small-molecule drug candidates advancing into preclinical studies. They leverage advancing technology and scientific breakthroughs to accelerate discovery and empower us to invent and create, and ultimately save one billion lives.
Details
Category
Where AI Leaders Stay Informed
The latest AI intelligence, case studies, and research — delivered to your inbox every week.
Free to read. Unsubscribe anytime.